Saturday, September 18, 2021

Pfizer

Moderna Covid vaccine edges Pfizer in new US research

The Moderna vaccine elicited higher levels of antibodies compared to Pfizer and Johnson & Johnson for a key part of the virus' spike protein, which it uses to invade cells.

US could okay Pfizer jab for kids aged 5-11 in October, sources say

The timeline is based on the expectation that Pfizer will have enough data from clinical trials to seek emergency use authorisation for that age group towards the end of this month.

EU watchdog studying data on Pfizer booster dose

The EMA says it will carry out a speedy evaluation of the data, with an outcome expected 'within the next few weeks'.

Aussie PM seeks quicker reopening after Covid vaccine swap with Britain

This comes as Australia records its biggest one-day rise in Covid-19 infections, with 1,657 new cases and 13 deaths reported in the past 24 hours.

Vaccine protection wanes within 6 months, says phone app study

The Pfizer jab fell in effectiveness to 74% after five to six months while the AstraZeneca vaccine fell to 67% after four to five months.

Messenger RNA Covid jabs 66% effective against Delta, US study shows

Researchers note a number of caveats, including that the protection from vaccines could be waning over time anyway, and the 66% estimate is based on a relatively short study period with few infections.

US grants full approval for Pfizer Covid vaccine, triggering new mandates

The vaccine remains available under emergency use authorisation to children aged 12 to 15, but because it has now been fully approved, physicians may prescribe it to children under 12.

Pfizer Covid jab declines faster than AstraZeneca, study shows

Two doses of Pfizer have greater initial effectiveness against new Covid-19 infections, but this declines faster compared with two doses of AstraZeneca, Oxford researchers say.

Pfizer submits data for third dose approval in US

Pfizer and BioNTech say a booster shot could help reduce infection and disease rates in people who have previously been vaccinated and better control the spread of virus variants during the coming season.

No need yet to adapt Pfizer vaccine for Covid variants, says BioNTech chief

He says a decision should be made only if it is clear that the vaccine failed to work or is only offering sub-par protection against the virus.

WHO urges Covid vaccine makers to keep prices down

This follows reports that Pfizer-BioNTech and Moderna are upping the prices for their messenger RNA vaccines because they have adapted them to the new virus variants.

Israel approves Covid jabs for at-risk children aged 5-11

They will be offered a Pfizer-BioNTech dose of 0.1 millilitre, three times less than the standard vaccine.

Other News